The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The projected timeframe until cervical cancer elimination in Australia: a modelling study
Open accessAbstract
BACKGROUND: In 2007, Australia was one of the first countries to introduce a national human papillomavirus (HPV) vaccination programme, and it has since achieved high vaccination coverage across both sexes. In December, 2017, organised cervical screening in Australia transitioned from cytology-based screening every 2 years for women aged from 18-20 years to 69 years, to primary HPV testing every 5 years for women aged 25-69 years and exit testing for women aged 70-74 years. We aimed to identify the earliest years in which the annual age-standardised incidence of cervical cancer in Australia (which is currently seven cases per 100 000 women) could decrease below two annual thresholds that could be considered to be potential elimination thresholds: a rare cancer threshold (six new cases per 100 000 women) or a lower threshold (four new cases per 100 000 women), since Australia is likely to be one of the first countries to reach these benchmarks. METHODS: In this modelling study, we used Policy1-Cervix-an extensively validated dynamic model of HPV vaccination, natural history, and cervical screening-to estimate the age-standardised incidence of cervical cancer in Australia from 2015 to 2100. We incorporated age-specific coverage of the Australian National HPV Vaccination Program in girls, including the catch-up programme, and the inclusion of boys into the vaccine programme from 2013, and a change from the quadrivalent to the nonavalent vaccine from 2018. We also modelled the effects of the transition to primary HPV screening. We considered two scenarios for future screening recommendations regarding the cohorts who will be and who have been offered the nonavalent vaccine: either that HPV screening every 5 years continues, or that no screening would be offered to these women. FINDINGS: We estimate that, in Australia, the age-standardised annual incidence of cervical cancer will decrease to fewer than six new cases per 100 000 women by 2020 (range 2018-22), and to fewer than four new cases per 100 000 women by 2028 (2021-35). The precise year of attaining these rates is dependent on the population used for age-standardisation, HPV screening behaviour and test characteristics, the incremental effects of vaccination of men on herd immunity in women, and assumptions about the future frequency of benign hysterectomies. By 2066 (2054-77), the annual incidence of cervical cancer will decrease and remain at fewer than one case per 100 000 women if screening for HPV every 5 years continues for cohorts who have been offered the nonavalent vaccine, or fewer than three cases per 100 000 women if these cohorts are not screened. Cervical cancer mortality is estimated to decrease to less than an age-standardised annual rate of one death per 100 000 women by 2034 (2025-47), even if future screening is only offered to older cohorts that were not offered the nonavalent vaccine. INTERPRETATION: If high-coverage vaccination and screening is maintained, at an elimination threshold of four new cases per 100 000 women annually, cervical cancer could be considered to be eliminated as a public health problem in Australia within the next 20 years. However, screening and vaccination initiatives would need to be maintained thereafter to maintain very low cervical cancer incidence and mortality rates. FUNDING: National Health and Medical Research Council (Australia).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,501
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD
Ahmad, O. B., Boschi-Pinto, C., López, A. D., Murray, C. J. L., Lozano, R., & Inoue, M. (2000) · Cited by 1,957
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Li, N., Franceschi, S., Howell‐Jones, R., Snijders, P. J. F., & Clifford, G. M. (2011) · International Journal of Cancer · doi:10.1002/ijc.25396 · Cited by 1,066
Cancer mortality for selected sites in 24 countries
栗原, 登., & 瀬木, 三. (1960) · Medical Entomology and Zoology · Cited by 871
Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, S., & Castellsagué, X. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30099-7 · Cited by 824
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Dei Tos, A. P., Kunkler, I., Otter, R., Licitra, L., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 809
Brisson, M., Bénard, É., Drolet, M., Bogaards, J. A., Baussano, I., Vänskä, S., Jit, M., Boily, M.-C., Smith, M. A., Berkhof, J., et al. (2016) · The Lancet Public Health · doi:10.1016/s2468-2667(16)30001-9 · Cited by 307
Self-citationImpact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
Gertig, D. M., Brotherton, J. M., Budd, A. C., Drennan, K., Chappell, G., & Saville, A. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-227 · Cited by 277
Self-citation
Cited by
Canfell, K., Kim, J. J., Brisson, M., Keane, A., Simms, K. T., Caruana, M., Burger, E. A., Martin, D., Nguyen, D. T. N., Bénard, É., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30157-4 · Cited by 650
Self-citationSimms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J.-B., Soerjomataram, I., Castle, P. E., Bray, F., & Canfell, K. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30836-2 · Cited by 486
Self-citationVaccine Safety: Myths and Misinformation
Geoghegan, S., O’Callaghan, K. P., & Offit, P. A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00372 · Cited by 275
“Complete eradication worldwide will ultimately require the cessation of use of trivalent OPV, a strategy currently being implemented by the WHO through a synchronized switch to a bivalent oral polio vaccine, successfully implemented in 150 countries as of 2016 (Hampton et al., 2016).”
Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts
Sankaranarayanan, R., Basu, P., Kaur, P., Bhaskar, R., Singh, G. B., Denzongpa, P., Grover, R. K., Sebastian, P., Saikia, T., Oswal, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30531-5 · Cited by 136
Whitworth, H. S., Gallagher, K. E., Howard, N., Mounier-Jack, S., Mbwanji, G., Kreimer, A. R., Basu, P., Kelly, H., Drolet, M., Brisson, M., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.12.017 · Cited by 118
Metadata
- Authors
- Hall, M. T., Simms, K. T., Lew, J.-B., Smith, M. A., Brotherton, J. M., Saville, M., Frazer, I. H., & Canfell, K.
- Venue
- The Lancet Public Health
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 4
- Issue
- 1
- Pages
- e19-e27
- ISSN
- 2468-2667 (ISSN-L)
- OpenAlex
- W2894633078
- Cited by
- 440
- References
- 29
- FWCI
- 32.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The projected timeframe until cervical cancer elimination in Australia: a modelling study. https://app.cochat.ai/papers/10.1016/s2468-2667(18)30183-x
- The paper
- Hall, M. T., Simms, K. T., Lew, J.-B., Smith, M. A., Brotherton, J. M., Saville, M., Frazer, I. H., & Canfell, K. (2019). The projected timeframe until cervical cancer elimination in Australia: a modelling study. The Lancet Public Health. https://doi.org/10.1016/s2468-2667(18)30183-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.